A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND

被引：0
|
作者：
O'Shaughnessy, Joyce
Basho, Reva
Lustberg, Maryam
Lyman, Gary H.
Prahladan, Manoj
James, Gareth D.
Varghese, Della
Lujan, Flavia
Tesch, Hans
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-17-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-17-02
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
    Dhanushkodi, Manikandan
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 556 - 558
  • [32] Safety of trastuzumab deruxtecan and radiation therapy combination in HER2-positive metastatic breast cancer patients
    Visani, L.
    Ratosa, I.
    Ribnikar, D.
    Becherini, C.
    Bertini, N.
    Bonaparte, I.
    Stefanovski, D.
    Dobnikar, N.
    Desideri, I.
    Mattioli, C.
    Valzano, M.
    Banini, M.
    Salvestrini, V.
    Bernini, M.
    Tommasi, C.
    Nori, J.
    Orzalesi, L.
    Bianchi, S.
    Livi, L.
    Meattini, I.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 60 - 61
  • [33] Trastuzumab deruxtecan, its efficacy in patients with metastatic HER2-positive breast cancer: a systematic review
    Fernhandho, V.
    Jhoputri, C. Fricilia
    Julian, L.
    Kurniawan, A.
    Huang, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1337 - S1337
  • [34] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
    Haddley, K.
    DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
  • [35] Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
    Yamashita, Toshinari
    Sohn, Joo Hyuk
    Tokunaga, Eriko
    Niikura, Naoki
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yee Soo
    Xu, Binghe
    Wang, Xiaojia
    Im, Seock-Ah
    Li, Wei
    Lu, Yen-Shen
    Aguilar, Cecilia Orbegoso
    Nishijima, Soichiro
    Nishiyama, Yuji
    Sugihara, Masahiro
    Modi, Shanu
    Tsurutani, Junji
    BREAST CANCER, 2024, 31 (05) : 858 - 868
  • [36] Trastuzumab and Deruxtecan Combination for Survival Benefit in Patients with HER2-low Breast Cancer
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (10)
  • [37] Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
    Nakajima, Hiromichi
    Harano, Kenichi
    Nakai, Tokiko
    Kusuhara, Shota
    Nakao, Takehiro
    Funasaka, Chikako
    Kondoh, Chihiro
    Matsubara, Nobuaki
    Naito, Yoichi
    Hosono, Ako
    Mitsunaga, Shuichi
    Ishii, Genichiro
    Mukohara, Toru
    BREAST, 2022, 61 : 136 - 144
  • [38] Fam-Trastuzumab Deruxtecan-nxki in metastatic HER2-low breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (07) : 779 - 779
  • [39] CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses
    Jerusalem, G.
    Park, Y. H.
    Yamashita, T.
    Hurvitz, S. A.
    Chen, S.
    Cathcart, J.
    Lee, C.
    Perrin, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S63 - S64
  • [40] Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer
    Bartsch, Rupert
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (09) : 901 - 910
12345